Mizuho Securities downgrades Circle to underperform and lowers target price to $50

AiCoin2026/07/19 06:11

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Bloomberg, Mizuho Securities analyst Dan Dolev has downgraded Circle from neutral to underperform, lowering its price target to $50, below the analyst average price target of $123. Dan Dolev believes Circle faces increased risk from intensifying stablecoin competition, with new projects such as OUSD potentially adding to Circle's pricing and profit margin pressures. Dan Dolev estimates Circle's adjusted EBITDA in 2027 to be $699 million, lower than the market consensus of $907 million. Circle's USDC distribution agreement with a certain exchange will be renegotiated in August.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12